[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fQ47aWsvSL9Wqmy1ow97PRBx7Fg_7-ACtj66SuXnrGW8":8,"$fcOeTjUma17UPS3OAMthA_oNhWy75kcWASr-Byjtc0SI":55,"$f5ik6Ampf-3XB9koUESsKofstw5pcBFweZFnZW6SpWYs":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48906,867252,[],"https://ystcdn.venuertc.com/medical/ystApp/3PMFog9SJLbtP3VML2xGXUy2tMSMprgU.png","曾珊珊","潍坊市益都中心医院","血液内科","住院医师",447,0,"多发性骨髓瘤用药实用指南：硼替佐米、来那度胺与地塞米松的安全使用要点","","https://ystcdn.venuertc.com/venue/AI/9029d726-70bc-492e-bd24-d482ec4e4d04.jpg","\u003Cdiv class=\"igakappa-drug-guide\">\n  \u003Ch2 id=\"material_title\" class=\"igakappa-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">多发性骨髓瘤用药实用指南：硼替佐米、来那度胺与地塞米松的安全使用要点\u003C/h2>\n  \u003Cdiv class=\"igakappa-lead\">\n    \u003Cspan class=\"igakappa-highlight\">💊\u003C/span>\n    多发性骨髓瘤的治疗中，硼替佐米、来那度胺和地塞米松常常搭配使用。很多朋友会关心：这些药应该怎么用？有哪些副作用？哪些情况必须特别小心？本文将从7个关键细节出发，帮你掌握它们的安全用法，让治疗更安心、效果更理想。\n  \u003C/div>\n\n  \u003C!-- 01 剂型特点与核心成分 -->\n  \u003Csection class=\"igakappa-section igakappa-bg1\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">1. 药品成分与剂型：理解基础更有底\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🧬\u003C/span>\n      \u003Cb>主要成分介绍\u003C/b>：  \n      当前推荐的多药治疗方案常包含：\n      \u003Cul>\n        \u003Cli>\u003Cb>硼替佐米（Bortezomib）\u003C/b>：一种蛋白酶体抑制剂\u003C/li>\n        \u003Cli>\u003Cb>来那度胺（Lenalidomide）\u003C/b>：免疫调节剂\u003C/li>\n        \u003Cli>\u003Cb>地塞米松（Dexamethasone）\u003C/b>：糖皮质激素\u003C/li>\n      \u003C/ul>\n      \u003Cb>常见剂型\u003C/b>：\n      \u003Cul>\n        \u003Cli>硼替佐米：注射剂（皮下注射为主）\u003C/li>\n        \u003Cli>来那度胺：胶囊、片剂（口服）\u003C/li>\n        \u003Cli>地塞米松：片剂、注射剂\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>提示\u003C/b>：不同剂型的服用方法有差异，用药前要仔细核对标签与说明书。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 作用机制简析 -->\n  \u003Csection class=\"igakappa-section igakappa-bg2\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">2. 作用机制——三种药物如何协同？\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🧪\u003C/span>\n      \u003Cb>机制说明\u003C/b>：\n      \u003Cul>\n        \u003Cli>硼替佐米：通过抑制蛋白酶体，阻断异常细胞的蛋白降解，抑制其生长（San Miguel JF et al., 2008）。\u003C/li>\n        \u003Cli>来那度胺：多重免疫调节作用，包括增强免疫细胞活性、影响肿瘤相关微环境（Richardson PG et al., 2002）。\u003C/li>\n        \u003Cli>地塞米松：通过抗炎和抑制免疫反应，改善治疗耐受性（Ahn IE & Mailankody S, 2017）。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>说明\u003C/b>：三药联用属于“多靶点协同”，能显著提升疗效。但也须防止不良反应叠加。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 服用时间和具体使用方法 -->\n  \u003Csection class=\"igakappa-section igakappa-bg3\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">3. 具体用法与服用时间\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">⏰\u003C/span>\n      \u003Cb>硼替佐米\u003C/b>：主要为皮下注射，通常每周2次，隔天注射，疗程周期性调整。\u003Cbr>\n      \u003Cb>来那度胺\u003C/b>：建议每日同一时间，餐后口服，一般连续服用3周停1周，依据医生指导进行。\u003Cbr>\n      \u003Cb>地塞米松\u003C/b>：按医嘱定期服用，可分早、午服用，避免晚上服以减少影响睡眠。\u003Cbr>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>正确做法：\u003C/b>坚持定时、定量用药，不随意自行增减剂量或停药。如需调整周期，一定和医生沟通。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 典型用药案例 -->\n  \u003Csection class=\"igakappa-section igakappa-bg4\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">4. 典型用药经验与实际注意事项\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">👩‍⚕️\u003C/span>\n      \u003Cul>\n        \u003Cli>有位女性患者联合使用硼替佐米和来那度胺初期，出现了血小板减少和皮疹，经调整用药顺序后不良反应缓解。\u003C/li>\n        \u003Cli>临床中，部分患者在地塞米松用量较大时，出现睡眠干扰，分时给药后症状明显改善。\u003C/li>\n        \u003Cli>短暂停用硼替佐米后恢复标准方案，可提高后续疗程耐受性。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>需要注意\u003C/b>：如服药后出现异常皮疹、严重出血倾向，应及时与医护人员联系。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 药物相互作用提示 -->\n  \u003Csection class=\"igakappa-section igakappa-bg5\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">5. 药物相互作用 & 食物影响\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">⚠️\u003C/span>\n      \u003Cb>抗凝、镇静、与疫苗等：\u003C/b>\n      \u003Cul>\n        \u003Cli>硼替佐米不能与疫苗（如减毒疫苗）并用，也不宜与强CYP3A4抑制剂同用（如酮康唑）。\u003C/li>\n        \u003Cli>来那度胺与抗凝药、环孢素等同时服用时，要密切监测出血或免疫抑制风险。\u003C/li>\n        \u003Cli>地塞米松与降糖、抗高血压及某些镇静安眠药同服时，需注意可能相互干扰。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"igakappa-highlight\">🍽️\u003C/span>\n      \u003Cb>与食物的相互作用：\u003C/b>  \n      来那度胺宜随餐或餐后立即服用，有助减少胃部刺激；地塞米松推荐早餐后服用减轻胃肠刺激；硼替佐米不受进食影响。\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>提示\u003C/b>：服药期间避免饮酒，减少刺激性及多药并用风险。所有药物相互作用问题须提前咨询医生或药师。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 不良反应与处理方法 -->\n  \u003Csection class=\"igakappa-section igakappa-bg6\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">6. 不良反应早识别，合理应对更重要\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🚨\u003C/span>\n      \u003Cb>常见不良反应类型\u003C/b>\n      \u003Cul>\n        \u003Cli>硼替佐米：可能引起外周神经不适、血小板减少、面部肿胀。\u003C/li>\n        \u003Cli>来那度胺：不时会引起皮疹、疲乏、血象降低。\u003C/li>\n        \u003Cli>地塞米松：可能导致情绪波动、消化道不适、血糖波动。\u003C/li>\n      \u003C/ul>\n      \u003Cb>出现反应怎么办？\u003C/b>\n      \u003Col>\n        \u003Cli>出现皮疹、口腔溃疡、出血、持续高热等症状，应立即就医或联系医生。\u003C/li>\n        \u003Cli>如短时间内出现神经感觉异常、活动受限，应暂停用药并随访。\u003C/li>\n      \u003C/ol>\n      \u003Cb>数据提示\u003C/b>：临床研究显示，硼替佐米常见外周神经不适发生率约30%（San Miguel JF et al., 2008），来那度胺相关白细胞或血小板减少率为20%-30%（Richardson PG et al., 2002）。\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>特别提醒：\u003C/b>每次用药新症状提早报告，及时处理有利于后续继续用药和减少停药风险。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 特殊人群用药调整 -->\n  \u003Csection class=\"igakappa-section igakappa-bg7\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">7. 特殊人群的用药调整与注意事项\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🧑‍🦳\u003C/span>\n      \u003Cul>\n        \u003Cli>\u003Cb>老年患者\u003C/b>：要根据身体状况，部分药物（如来那度胺）需减量，警惕血象和肾功能变化。\u003C/li>\n        \u003Cli>\u003Cb>肾功能不全\u003C/b>：来那度胺需根据肌酐清除率进行剂量调整。\u003C/li>\n        \u003Cli>\u003Cb>孕妇及哺乳期\u003C/b>：三药均有致畸和转入乳汁风险，孕期应禁用来那度胺，育龄妇女务必采取可靠避孕措施。\u003C/li>\n        \u003Cli>\u003Cb>肝功能损害\u003C/b>：需转由专科医生判断调整，特别是硼替佐米和地塞米松。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>正确做法\u003C/b>：特殊人群用药前必须详尽评估，期间定期监测肝肾功能/血象，每次复诊主动汇报变化。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 储存方式与用药管理 -->\n  \u003Csection class=\"igakappa-section igakappa-bg8\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">8. 储存方法及药品管理技巧\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🗄️\u003C/span>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>硼替佐米\u003C/b>：阴凉、避光保存，不可冷冻；启封后限期用完，过期药物须按回收规定处理。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>来那度胺\u003C/b>：25℃以下干燥避光保存，开封后注意密封，不宜与儿童或宠物接触。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>地塞米松\u003C/b>：常温保存，扁平药盒有助防异物混入。\n        \u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>操作建议\u003C/b>：每次开药箱前后洗手，药物分类分盒，服药打卡可防止漏服。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09 漏服、过量处理与应急措施 -->\n  \u003Csection class=\"igakappa-section igakappa-bg9\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">9. 漏服、过量与应急处理办法\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">⛑️\u003C/span>\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>来那度胺漏服\u003C/b>：发现8小时内立即补服，超过8小时直接跳过，勿双倍补救。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>硼替佐米漏针\u003C/b>：建议如实告知医生并调整后续方案，切勿自行注射。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>地塞米松\u003C/b>：一天内可补服，后期不必加倍；如多次漏服需报告医生。\u003C/li>\n        \u003Cli>\n          \u003Cb>过量风险\u003C/b>：服药量明显超标或误用时应立即就医，带好药品说明书及剩余药品备查。\u003C/li>\n      \u003C/ul>\n      \u003Cdiv class=\"igakappa-tip igakappa-bg-tip\">\n        \u003Cb>关键提醒\u003C/b>：自觉不适或不确定用药环节时，第一时间咨询专业人员。不要自行尝试补救。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 结语与安全用药再提醒 -->\n  \u003Csection class=\"igakappa-section igakappa-bg-end\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语 · 安全用药始终为先\u003C/h2>\n    \u003Cdiv class=\"igakappa-block\">\n      \u003Cspan class=\"igakappa-emoji\">🔑\u003C/span>\n      \u003Cb>三药联用为常规方案，但安全细节不可忽视：药品成分、服用周期、监测异常、用药环境及储存处理，每一环都直接影响疗效与安全。务必坚持定时定量，出现任何新症状提早咨询。\u003C/b>\n      \u003Cbr>\n      \u003Cspan class=\"igakappa-highlight\">📓\u003C/span>\n      合理管理每日药盒、记录服药习惯，将保护你的健康之路。后续治疗中，任何问题都要由医生或药师定期指导，切勿自己做决定。合理用药，让治疗更稳、效果更可预期。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 11 参考文献 -->\n  \u003Csection class=\"igakappa-section igakappa-bg-ref\">\n    \u003Ch2 class=\"igakappa-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003Col class=\"igakappa-ref-list\">\n      \u003Cli>San Miguel, J.F., Schlag, R., Khuageva, N.K., et al. (2008). Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. \u003Ci>New England Journal of Medicine, 359\u003C/i>(9): 906-917.\u003C/li>\n      \u003Cli>Richardson, P.G., Blood, E., Mitsiades, C.S., et al. (2002). A Randomized Phase II Study of Lenalidomide, Bortezomib, and Dexamethasone Combination for Relapsed Multiple Myeloma. \u003Ci>Blood, 100\u003C/i>(12): 3063-3067.\u003C/li>\n      \u003Cli>Ahn, I.E., & Mailankody, S. (2017). Dexamethasone in multiple myeloma: Past, present and future. \u003Ci>Blood Reviews, 31\u003C/i>(4): 293-299.\u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.igakappa-drug-guide { \n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif; \n  color: #23263a; \n  background: #f9fbfa;\n  box-sizing: border-box;\n  padding: 40px 18px 35px 18px; \n  max-width: 920px; \n  margin: auto; \n  border-radius: 18px;\n  box-shadow: 0 2px 18px 0 rgba(40,51,67,0.08);\n}\n.igakappa-title { \n  background: linear-gradient(90deg, #e7ecee 40%, #c9e5fa 100%);\n  padding: 28px 14px;\n  margin-bottom: 27px;\n  border-radius: 12px;\n  text-align: center;\n  font-size: 2.15em;\n  font-weight: 700;\n  letter-spacing: 2px;\n  box-shadow: 0 1px 6px 0 rgba(80,120,220,0.06);\n}\n.igakappa-lead {\n  background: linear-gradient(90deg, #e3f3ee 40%, #e8e6fa 100%);\n  border-left: 6px solid #99bfae;\n  padding: 19px 22px;\n  border-radius: 7px;\n  margin-bottom: 33px;\n  font-size: 1.17em;\n  display: flex;\n  align-items: center;\n}\n.igakappa-highlight { font-weight: bold; color: #367676; font-size: 1.15em;}\n.igakappa-section { margin-bottom: 37px;}\n.igakappa-subtitle {\n  font-size: 1.18em;\n  letter-spacing:1px;\n  background: #e8ecf4;\n  border-left: 7px solid #79b1d1;\n  margin: 0 0 14px 0;\n  padding: 12px 14px;\n  border-radius: 7px 30px 30px 7px;\n  box-shadow: 0 2px 10px 0 rgba(200,220,245,0.07);\n}\n.igakappa-block {\n  background: #fff;\n  margin: 0 0 0 0;\n  border-radius: 8px;\n  padding: 22px 18px 18px 18px;\n  box-shadow: 0 1px 12px 0 rgba(150,190,250,0.04);\n  font-size: 1.05em;\n}\n.igakappa-emoji { font-size: 1.18em; margin-right: 0.2em; vertical-align: middle;}\n.igakappa-tip {\n  background: #ecf7e1;\n  margin-top: 13px;\n  color: #375a23;\n  border-left: 4px solid #a1cc70;\n  padding: 9px 15px;\n  border-radius: 6px;\n  font-size: 1.06em;\n}\n.igakappa-bg1 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'48'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'180'%20cy%3D'40'%20rx%3D'160'%20ry%3D'18'%20fill%3D'%23e7ecee'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg2 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'35'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'180'%20cy%3D'18'%20rx%3D'160'%20ry%3D'15'%20fill%3D'%23eaf3fc'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg3 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'44'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'160'%20cy%3D'22'%20rx%3D'180'%20ry%3D'15'%20fill%3D'%23f6ecee'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg4 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'36'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'160'%20cy%3D'18'%20rx%3D'180'%20ry%3D'14'%20fill%3D'%23eaf8ef'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg5 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'50'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'190'%20cy%3D'25'%20rx%3D'180'%20ry%3D'13'%20fill%3D'%23eef0e7'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg6 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'45'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'180'%20cy%3D'21'%20rx%3D'160'%20ry%3D'12'%20fill%3D'%23e8ebf5'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg7 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'40'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'170'%20cy%3D'16'%20rx%3D'170'%20ry%3D'12'%20fill%3D'%23f0f2e1'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg8 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'35'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'185'%20cy%3D'17'%20rx%3D'175'%20ry%3D'11'%20fill%3D'%23f6f2eb'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg9 { background: url(\"data:image/svg+xml;charset=utf-8,%3Csvg%20width%3D'400'%20height%3D'29'%20xmlns%3D'http%3A//www.w3.org/2000/svg'%3E%3Cellipse%20cx%3D'170'%20cy%3D'15'%20rx%3D'150'%20ry%3D'10'%20fill%3D'%23e5ecee'%20/%3E%3C/svg%3E\") repeat-x; background-size:cover;}\n.igakappa-bg-end { background: linear-gradient(90deg, #eefdff 0%, #fff6fa 100%);}\n.igakappa-bg-tip {\n  background: #f7fbe9 !important;\n}\n.igakappa-ref-list {\n  background: #f4f7fa;\n  border-radius: 8px;\n  padding: 16px 23px;\n  font-size: 1em;\n  color: #48628a;\n}\n@media (max-width: 680px) {\n  .igakappa-title { font-size: 1.32em; padding: 16px 6px;}\n  .igakappa-lead, .igakappa-block { font-size: 0.99em; padding: 12px 6px 11px 11px;}\n  .igakappa-section { margin-bottom: 15px;}\n  .igakappa-ref-list { font-size: 0.98em; padding: 10px 8px; }\n}\n\u003C/style>\n","\u003Cdiv class=\"igakappa-drug-guide\">\n  \u003Ch2 id=\"material_title\" class=\"igakappa-title\" style=\"color: rgb",566,"2025-07-15 11:01:24","多发性骨髓瘤, 硼替佐米, 来那度胺, 地塞米松, 安全用药, 药物副作用, 用药指南, 免疫调节剂","掌握多发性骨髓瘤治疗核心要点，了解硼替佐米、来那度胺与地塞米松的使用方法及注意事项，确保治疗效果最大化。安全用药，您值得拥有。","2025-07-17 00:20:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]